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Abstract 1 
Background  2 
Reduction in sensorimotor function of the upper limb is a common and persistent impairment after 3 
stroke, and less than half of stroke survivors recover even basic function of the upper limb after a 4 
year. Previous work in stroke has shown that repetitive sensory stimulation (RSS) of the upper limb 5 
may benefit motor function. As yet, there have been no investigations of RSS in the early-acute 6 
period despite this being the time window during which the neuroplastic processes underpinning 7 
sensorimotor recovery are likely to occur.  8 
Methods 9 
A single-blinded stratified randomised controlled feasibility study was undertaken at 2 NHS acute 10 
trusts to determine the recruitment rate, intervention adherence, and safety and acceptability of an 11 
RSS intervention in the early after stroke. Participants were recruited within two weeks of index 12 
stroke.  Stratified on arm function, they were randomised to receive either 45 minutes of daily RSS 13 
and usual care or usual care alone (UC) for two weeks. Changes from baseline on the primary 14 
outcome of the Action Research Arm Test (ARAT) to measurements taken by a blinded assessor were 15 
examined after completion of the intervention (2 weeks) and at 3 months from randomisation.  16 
Results  17 
Forty patients were recruited and randomised (RSS: n=23; UC: n=17) with a recruitment rate of 9.5% 18 
(40/417) of patients admitted with a stroke of which 52 (12.5%) were potentially eligible, with 10 19 
declining to participate for various reasons. Participants found the RSS intervention acceptable and 20 
adherence was good. The intervention was safe and there were no serious adverse events. 21 
 22 
 23 
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Conclusions 1 
This study indicates that recruitment to a trial of RSS in the acute period after stroke is feasible. The 2 
intervention was well tolerated and appeared to provide additional benefit to usual care. In addition 3 
to a definitive trial of efficacy, further work is warranted to examine the effects of varying doses of 4 
RSS upon arm function and the mechanism by which RSS induces sensorimotor recovery in the acute 5 
period after stroke.  6 
Trial registration: This study was registered with ISRCTN in January 2017 (ISRCTN registry no: 7 
ISRCTN17422343; IRAS Project ID: 215137). 8 
Keywords: Stroke, Upper Limb rehabilitation, Repetitive Sensory Stimulation   9 
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Background 1 
Over 15 million people experience a stroke each year worldwide and, in high-income countries, 2 
stroke is the single main cause of acquired disability.[1] There are more than 1.2 million stroke 3 
survivors living in the UK with over 100,000 new cases of stroke each year.[2].  4 
 5 
Advances in the acute care have dramatically reduced stroke mortality [3] but recovery of 6 
sensorimotor function of the upper limb remains problematic. Whilst two-thirds of stroke survivors 7 
go on to walk independently, less than 20% recover full upper limb function and over half do not 8 
regain basic functions of the upper limb after several years. [4, 5] 9 
 10 
Completing even simple Activities of Daily Living (ADLs) often requires a substantial level of upper 11 
limb ability and so persistent impairments in upper limb function produce negative effects upon 12 
daily functioning and significantly reduce independence.[6, 7] Consequently, improving upper limb 13 
function is a core element of stroke rehabilitation.[8] Current treatment guidelines emphasize that 14 
rehabilitation should include high numbers of repetitions of motor tasks (repetitive task training, 15 
RTT) to improve sensorimotor function after stroke.[9] Recent work has also identified a five-week 16 
critical window after stroke in which most of the neuroplasticity that underpins recovery of 17 
sensorimotor control of the upper limb occurs.[10] This period presents a short but sensitive phase 18 
of increased responsiveness to rehabilitation after stroke. It also indicates that the intensity of 19 
training is likely to be key in this 5 week period to maximise neuroplastic processes and optimise the 20 
recovery of the upper limb. However, in practice, delivering high intensity RTT in the acute and early 21 
subacute period after stroke is challenging. Difficulties arise as it requires participants to be 22 
consistently and highly motivated, and rehabilitation staff need to have the time and resources to 23 
support RTT.[11, 12]  24 
 25 
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Consequently, there is a clear and urgent need to develop and evaluate new treatments. Such 1 
treatments need to be delivered in the early, sensitive period after stroke, must not require 2 
significant increases in staff time, cannot be reliant on consistently high levels of motivation in 3 
people after stroke, and able to be used by people with severe hemiparesis. 4 
 5 
Repetitive sensory stimulation (RSS) is a largely passive treatment which has been recognized in 6 
healthy people to produce neuroplastic changes, similar to those elicited by repetitive task 7 
training.[13] These include lasting changes in corticospinal excitability which may be elicited via a 8 
GABA-ergic disinhibition and long-term potentiation produced by glutaminergic mechanisms [14].  9 
 10 
RSS interventions have predominantly been evaluated in studies of people many months or even 11 
years after stroke [15-19] with benefits to sensation, arm and hand function. Recently, a small 12 
randomised, sham-controlled trial evaluating a 2 week RSS intervention in people commenced in the 13 
early subacute stage[20] (at least 3 or 4 weeks) after stroke showed significant benefits to 14 
sensorimotor function including tactile discrimination and global hand function.[21] However, no 15 
studies have used RSS in the acute/very early subacute period (first few days or weeks) after stroke, 16 
despite this being likely to be the optimal period for recovery of sensorimotor function.[10] 17 
However, there may be practical factors which influence the feasibility and acceptability of using the 18 
RSS in the first few days after stroke and of recruiting to and conducting a trial of its effectiveness 19 
during this period. Therefore, a study was conducted to determine: the feasibility and acceptability 20 
of using RSS in the first 2 weeks after stroke (acute and early subacute period)[20]. Collectively this 21 
information will inform a future adequately sized randomised controlled clinical trial of RSS early 22 
after stroke.  23 
 24 
 25 
 26 
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Methods 1 
Study design 2 
The study was designed as a single-blind stratified randomised controlled trial, designed and funded 3 
to recruit and follow up 40 patients within one and half years. Patients were recruited at Stroke units 4 
at the Countess of Chester Hospital NHS Foundation Trust between January and November 2017 and 5 
at Basildon and Thurrock University Hospitals NHS Foundation Trust from September to November 6 
2017. Ethical approval was obtained from North West-Liverpool Central Research Ethics Committee 7 
(ref no: 16/NW/07/71). The recruitment was stopped as it enrolled the required number of patients. 8 
 9 
Participants  10 
Participants were included if they were over 18 and had suffered a unilateral, confirmed stroke in 11 
the past 2 days to 2 weeks, which had left them with sensorimotor deficits of their arm. Those who 12 
did not have a National Institute of Health Stroke Scale (NIHSS) arm motor score between 1 and 4 13 
(NIHSS arm score ranges from 0: no weakness to 4: no movement) and/or a pre-stroke modified 14 
Rankin scale score (mRS) between 0 and 3 (where 0=no disability, 3=Moderate disability, requiring 15 
some help, but able to walk unassisted) were not included [23,26]. Both of these tools were chosen 16 
as they are widely recognised in both clinical and research settings and are recommended by the 17 
Stroke Rehabilitation Research Roundtable. [25] Potential participants were also excluded if they 18 
had epilepsy, a permanent pacemaker, dermatitis or oedema of the affected hand or if they could 19 
not give verbal or written consent. 20 
After going through the inclusion and exclusion criteria, all eligible patients were invited by a Good 21 
Clinical Practice trained healthcare professional to take part in this trial. As this was a feasibility trial, 22 
only those who could provide a signed informed consent or witnessed verbal consent were allowed 23 
to participate in the trial. 24 
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Stratification and Randomisation 1 
After giving informed consent, participants were randomised to either the experimental group 2 
comprising 45 minutes of RSS delivered daily for 2 weeks via a glove plus usual care (RSS) or usual 3 
care (UC) alone. Randomisation was stratified by both NHS trust and the patients NIHSS arm score 4 
(1-2; 3-4). Block randomisation with block sizes, 2, 4 and 6 were used to generate the randomisation 5 
lists for each trust and NIHSS arm score. Group allocations were placed in serially numbered sealed 6 
envelopes to be opened after consenting, this was done by the trial statistician. Each trust had two 7 
randomisation lists, one for each NIHSS are score strata. Researchers undertaking recruitment and 8 
randomisation had no prior knowledge or involvement in the generation of the randomisation lists.  9 
 10 
Interventions  11 
The RSS group were provided with an appropriate sized glove and stimulator box (Figure 1). The RSS 12 
glove was placed on the affected hand by the participant with aid from a rehabilitation assistant 13 
and/or a family member, as required. Supra-sensory pulses were delivered at a frequency of 20 Hz 14 
with an intensity of 1 to 20mA by electrodes within each glove positioned on the distal and proximal 15 
phalanges, providing stimulation to all fingers. The intensity of the current was increased to the 16 
highest level that the participant could tolerate and, once this intensity was reached, the participant 17 
received 45 minutes of stimulation. This duration was chosen as 30 minutes of supra-sensory hand 18 
stimulation has been shown to increase cortical excitability, which plateaus by 45 minutes [27-29]. 19 
RSS was repeated daily for two weeks (14 sessions, total time: 630 minutes)[21].  20 
Usual Care (UC) comprised a range of individually tailored interventions (necessary for the individual 21 
patient) delivered by physiotherapists and occupational therapists who were specialised in 22 
neurological rehabilitation. The RSS and UC groups were not matched for time and attention but the 23 
therapy duration of UC and RSS were noted after each treatment session (Table 1). 24 
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Acceptability was evaluated by sending 21 participants/carers in the RSS group at Chester a postal 1 
questionnaire after the completion of the study. The questionnaire was developed specifically for 2 
this study and comprised 10 open, free-text questions (see appendix 1). These were completed by 3 
the participant and/or their carer and asked about: their perception of the RSS glove, ease of use, 4 
positive and negative aspects of using it, whether they felt it helped, if so how, what they did when 5 
wearing it, would they recommend it to others and would they use it again in future plus provide any 6 
other comments about their experience. 7 
Measurements 8 
Demographic data comprising type of stroke (ischaemic or haemorrhagic), pre-stroke and immediate 9 
post-stroke function (mRS), stroke severity (NIHSS) was collected on all participants prior to 10 
commencement of the study. Outcome tools that were anticipated to be the primary indicators of 11 
effectiveness in a future trial were used to measured arm function. The anticipated primary outcome 12 
tool was the Action Research Arm Test (ARAT). The ARAT is a 19 item observational tool. Items are 13 
categorised into four subscales (grasp, grip, pinch and gross movement) with increasing difficulty. A 14 
participant’s performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 15 
(movement performed normally). It is well-validated in stroke rehabilitation and is recommended as 16 
the key functional outcome tool of arm activities after stroke by an international, multi-disciplinary 17 
expert group. [25] Total scores either indicate no upper limb capacity (0-10), poor capacity (11-21), 18 
limited capacity (22-42), notable capacity (43-54) or full capacity (55-57).[33,34] The ARAT was 19 
assessed by an independent blinded assessor by viewing the video recording of the participants 20 
performing completing this test both at two weeks and at the end of three months from the 21 
randomisation.[30]  22 
Secondary anticipated outcomes included the Fugl-Meyer Assessment of upper extremity outcome 23 
tool (FMA-UE) which is a well-recognised and recommended observational measure of upper limb 24 
impairment [25].  This test comprises 4 sections for the upper limb and each of the 33 items is a 25 
10 
 
scored on a 3 point Likert scale (0=cannot perform to 3=performs fully). A maximum score of 66 1 
indicates full upper limb capacity, a score between 48 to 53 indicates notable capacity, 32 to 47 2 
limited capacity, 23 to 31 poor capacity and 0 to 22 no capacity. The  time taken to complete the 3 
nine hole peg test (NHPT) was also used to indicate dexterity.[30,31] These outcomes were re-4 
assessed two weeks after starting the intervention and at 3 months follow up by a blinded assessor 5 
who viewed video recordings of participants completing the items on each outcome tool.  6 
Analysis  7 
Feasibility was evaluated by examining:  8 
• Ease of recruitment expressed as a proportion of enrolled participants/proportion of the 9 
screened participants from inpatients on the stroke units 10 
• Adherence of using the RSS glove (expressed as a percentage of the maximum time of 630 11 
minutes if the glove was worn for 45 minutes, every day for 2 weeks). This was collected 12 
both manually by asking patients or their family member to complete a daily treatment diary 13 
during the treatment period which was subsequently compared with the data downloaded 14 
from the RSS generator, so was not reliant on participant recollection. Reasons for non-15 
adherence were collected, where possible.  16 
• Safety of the intervention over 3 months (including the 2 week intervention period). Several 17 
potential adverse events were specifically identified and were:  18 
o any damage to the skin integrity of the hand (including ulcers, necrosis) within 30 19 
days of enrolment,  20 
o epileptic seizures,  21 
o the presence of a painful shoulder on the affected upper limb,  22 
o contracture of the affected hand, and  23 
o any other adverse events reported by the investigator. 24 
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Acceptability was judged from RSS participant’s responses to the postal questionnaire sent after the 1 
study had finished. 2 
Changes in the anticipated primary and secondary outcome measures for a future trial were 3 
examined using descriptive statistics; in this application non-parametric methods were used due to 4 
the data being not normally distributed. Logistic regression was also used to assess the association 5 
between intervention and outcome, both directly and adjusted for baseline ARAT scores. It should 6 
be noted that as this is pilot study the study is not powered to detect differences in outcome 7 
measures and as a consequence no formal hypothesis testing is undertaken. The changes in scores in 8 
RSS and UC groups were compared to published values of minimal clinical important differences 9 
(MCID) in acute and chronic stroke. [32-35] A pre-specified set of criteria of “successful outcome” for 10 
the primary outcome measure (ARAT) was developed based on the improvement in the ARAT score 11 
used by Shaw et al in BoTULS trial.[37] A successful outcome was defined as:  12 
▪ >3 points improvement if baseline ARAT score of 0-3. 13 
▪ >6 points improvement if baseline ARAT score of 4-51 14 
▪ An ARAT score of 57 or above if baseline ARAT score was >51   15 
Using these pre-specified criteria of good outcome, a calculation using a 80% power was used to 16 
indicate the sample size needed to detect an increase in the  proportion of good outcomes from 45% 17 
to 57.5% with treatment ( α = 0.05, 2-tailed). [40] All data were analysed using IBM SPSS software 18 
version 24.  19 
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Results 1 
Feasibility 2 
From 9th of January 2017 to 10th of November 2017 (10 months), 417 people admitted after a stroke 3 
were screened and 52 of them were eligible to participate; of which 40 (23 females, four left 4 
handed) were included in the trial, giving a recruitment rate of 77% of those eligible to participate. 5 
The reasons for exclusions non-recruitment and participant flow through the study are illustrated in 6 
Figure 2.  7 
After providing consent, participants were randomised to usual care (UC, n=17) or RSS groups (RSS, 8 
n=23). All participants had suffered an ischaemic stroke except one who had a haemorrhagic stroke 9 
and was randomised to the RSS group. Twenty eight participants had known hypertension (RSS=16, 10 
UC=12), 12 had a history of AF (RSS=5, UC=2) and 5 had survived a previous stroke (RSS=3, UC=2). 11 
Seven participants had a stroke affecting their dominant side in the RSS group, with 8 having a stroke 12 
on their dominant side in the UC group.  Baseline characteristics of participants in the RSS and UC 13 
groups are shown in Table 1. 14 
Both groups received over 18 hours of therapy during the intervention but, as groups were not 15 
matched for time and attention, the RSS group received somewhat more (combined occupational 16 
and physio therapy; RSS median, range: 1305, 70-7095 minutes; UC: 1085; 0-3380 minutes). 17 
However, the amount of upper limb specific physiotherapy time was not different between the 18 
groups (combined upper limb physiotherapy; RSS median, range: 210, 135-335 minutes; UC: 215; 0-19 
445 minutes).    20 
Adherence to the RSS intervention appeared good. Eleven participants (48%) completed 45 minutes 21 
in every session and so received the maximum dose of RSS (630 minutes, 100%) and a further 8 22 
(35%) received over 75% of the maximum dose (over 495 minutes). Only two participants (4%) 23 
completed less than 50% of the sessions as they had a carotid surgery (endarterectomy) during the 24 
13 
 
study period. Other reasons for non-completion of all the sessions was machine dysfunction (n=2, 1 
9%), and patients choice (n=6, 26%). 2 
Few adverse events (Table 2) were recorded and were generally mild. Shoulder pain was reported by 3 
8(35%) people in the RSS group and 5(29%) in the UC group.  One person in the RSS group reported 4 
pain in the web space of their thumb which had been there since having their stroke and was not 5 
worsened by the intervention. No participants had any seizures, but one participant in the UC passed 6 
away during the study period.  7 
Table 2: Adverse event 8 
 RSS + Standard treatment Standard treatment 
Shoulder Pain                                           No 
                                                                    Yes 
15 (65%) 
  8 (35%) 
12 (71%) 
  5 (29%) 
Hand pain                                                  No 
                                                                    Yes 
22 (96%) 
   1 (4%) 
17 (100.0%) 
 9 
Acceptability to participants 10 
Nine participants and/or their carers from the RSS group completed and returned questionnaires 11 
(return rate: 43% of 21 participants). Two reported that they found the RSS glove easy to use, 7 12 
found it ‘fiddly’ initially but 6 of these 7 reported that this got easier with practice. Three 13 
participants felt the glove had not worked, but 3 participants felt they had more movement in their 14 
hand after the intervention. Five participants reported no negative effects after using the glove, 2 15 
felt it was slightly painful and the remaining two respondents reported that it was quite tight with 16 
one noting that their skin appeared dry after using it. Five people would recommend the RSS glove 17 
to other people who have had a stroke whilst one would not. Two would recommend it if it was 18 
shown to be beneficial, whilst one participant stated it was worth trying. 19 
Outcome 20 
14 
 
Changes from baseline to two weeks and three months on the outcome measures used are presented 1 
in Table 3. A change in the ARAT scores indicating a successful outcome from baseline was seen for 16 2 
(70%) people in the RSS group and 8 (47%) in the UC group at 2 weeks. At 3 months, this increased in 3 
both groups (RSS: 17 people, 74%; UC: 11 people, 69%).   4 
 5 
Table 3: Outcome  6 
Outcome tool 
 
2 weeks 3 months 
RSS 
(n=23) 
UC 
(n=17) 
RSS 
(n=23) 
UC# 
(n=16) 
Change in ARAT                                  
Median (IQR) 
                                                 
Range  
 
8 (19) 
 
0 – 38 
 
3 (16) 
 
-9 - 30 
 
16 (30) 
 
0-51 
 
7 (23) 
 
0-55 
Change in FMA-UE                             
Median (IQR) 
                                                             
Range  
 
12 (15) 
 
-1 – 33 
 
6 (12) 
 
-11 - 22 
 
16 (14) 
 
-6 – 45 
 
11.5 (13) 
 
-6 -31 
Change in NHPT*                             
 
Median (IQR) 
                                                             
Range 
 
 
-6 (-162) 
 
-282 – 17 
 
 
0 (-82) 
 
-252 - 26.1 
 
 
-55 (-163) 
 
-269 – 0 
 
 
-9 (-206) 
 
-265 – 11.8 
 7 
# indicates n=16 as 1 participant in the UC group died before 3 months. Positive changes indicate 8 
improvement except for NHPT.  ARAT – Action Research Arm Test; FMA UE Fugl Meyer Assessment 9 
15 
 
Upper Extremity, NHPT – nine hole peg test* if participants could not undertake the test, they were 1 
scored as taking 300 seconds. 2 
 3 
To further quantify the improvement in outcome after using the intervention, logistic regression was 4 
used to calculate an odds ratio that showed that after using the glove the patient was over 3 times 5 
more likely to reach a good outcome at 2 weeks (OR = 3.27, 95% Confidence interval (0.88, 12.13)) 6 
and 1.5 times at three months (OR = 1.55, 95% Confidence interval (0.44, 5.53)). As those in the 7 
intervention group had a lower baseline ARAT score, this variable was then added to the model to 8 
estimate an adjusted odds ratio. After adjusting for baseline ARAT score those patients who used the 9 
glove were still over 3 times more likely to achieve a good outcome at 2 weeks (Adjusted OR = 3.10, 10 
95% confidence interval (0.79, 11.39)) and 1.3 times at three months (Adjusted OR = 1.36, 95% 11 
confidence interval 0.37, 5.02)). These differences are not statistically significant, but the study was 12 
not powered to detect a statistically significant difference. However, it provides sufficient evidence of 13 
efficacy to go forward to a definitive trial. 14 
The change in median ARAT and FME-UE score in both groups are illustrated in Figures 3 and 4 (for 15 
waterfall plots on individual changes in ARAT score please see the supplementary Figure 1A and 1B)  16 
In the RSS group, 10 participants (from 23, 44%) had a change exceeding the minimal clinical 17 
important difference (MCID, 12 points) in acute stroke[34] compared to 4 people (from 17, 24%) in 18 
the UC group exceeded the MCID at 2 weeks. At 3 months, the number of people in the RSS group 19 
who exceeded the MCID of 5.7 points on the ARAT for chronic stroke[33] increased to 16 (70%) and 20 
to 9 in the UC group (56%).  21 
The FMA-UE scores showed that 13 people in the RSS group exceeded the MCID of 9 points at 2 22 
weeks compared to 4 in the UC group[38, 39]. At three months, 15 people in the RSS group and 9 in 23 
the UC group had improved by over 9 points. On the NHPT 10 participants exceeded the minimal 24 
16 
 
detectable change of 33 seconds in the RSS group, compared to 5 in the UC group; these values were 1 
unchanged at 3 months.[39] 2 
Based on these results, the sample size needed for a definitive trial of effectiveness of RSS in the 3 
acute period after stroke will be 550 participants, including a 10% attrition rate. A trial with 247 4 
patients per group would have 80% power to detect an increase in the proportion of positive clinical 5 
outcomes from 45% to 57.5% using the intervention (α = 0.05, 2-tailed) [40]. If we upped the power 6 
to 90% then we would require 331 per group and again allowing for 10% attrition a total sample size 7 
of 736 would be required to detect an increase of 12.5% in the proportion of positive clinical 8 
outcomes.  9 
The full trial will use a centralised web-based computerised randomisation system usually used by 10 
our Clinical Trial Unit based at the University of Central Lancashire. 11 
  12 
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Discussion 1 
This is the first study to examine an RSS intervention in the acute, very early period after stroke and 2 
provides important data regarding the feasibility of a trial of RSS and the safety and acceptability of 3 
the RSS intervention during this time. The rehabilitation undertaken in the first few days and weeks 4 
after stroke is likely to be immensely influential on long-term outcomes[41, 42]. The finding of this 5 
study indicate that RSS intervention delivered in the acute and early subacute phases after 6 
stroke[21] appears safe and acceptable and may benefit upper limb function when used to augment 7 
usual care.  8 
Feasibility and acceptability 9 
The first aim of the study was to examine the feasibility of an RSS intervention during the early acute 10 
period after stroke. The majority of inpatients after stroke did not conform to the inclusion criteria 11 
(n=365) or declined to participate (n=10) resulting in a recruitment rate of 11%. The largest number 12 
of potential participants were excluded as they had no or very mild arm involvement after stroke 13 
and/or had significant functional restrictions prior to having their stroke. Other trials using forms of 14 
RSS have reported some challenges in recruiting suitable participants.[21] This may have been 15 
exacerbated in the current study as participants were approached in the first days after stroke and 16 
so may have been more likely to decline to participate whilst others were unable to clearly give 17 
informed consent due to cognitive or communication problems (n=37). These findings indicate that 18 
for a future trial of RSS, a multi centred design will be required to ensure the study is adequately 19 
powered and that different formats of presenting information and gaining consent for those with 20 
communication difficulties and/or cognitive problems should be considered to broaden inclusion. 21 
Once recruited to the study, adherence to the use of the RSS glove was good with 19 from 23 22 
participants completing over 75% of the entire treatment dose. There were few adverse events and 23 
those that were reported were relatively minor (dry skin, shoulder discomfort). There were no drop 24 
18 
 
outs from the RSS group, suggesting that the intervention was well tolerated. From those that 1 
returned the questionnaire, participants found the glove relatively easy to use after practice and 2 
familiarisation and most reported benefit. These findings agree with other reports of RSS in subacute 3 
stroke [21] and indicate that RSS may be an attractive treatment for people early after stroke but are 4 
limited as a standardised tool to quantify acceptability was not used, and it is not known why less 5 
than half of those asked returned their questionnaires and hence this part of the result should be 6 
interpreted with some caution.  7 
Changes after the intervention  8 
The ARAT, FMA-UE and 9HPT all indicated somewhat greater improvement in the RSS group when 9 
compared to the UC group, with benefits exceeding the MCID for the majority of RSS participants on 10 
the ARAT and FMA-UE. These outcomes were chosen as they are recommended by a recent 11 
roundtable for stroke rehabilitation experts and have demonstrated excellent validity, reliability and 12 
responsiveness to rehabilitation interventions for the upper limb after stroke [25]. Improvements on 13 
all outcomes were most marked immediately after the intervention period and the rate of 14 
improvement appeared to attenuate after the intervention had ceased. This might indicate that an 15 
intervention period longer than two weeks used in the current study might elicit even greater 16 
improvements. Few have used an intervention period of more than 2 weeks when evaluating RSS. 17 
Peurala et al. (2002) applied RSS twice a day for three weeks in 59 people with chronic stroke; 18 
Conforto et al., (2010) used it for three times a week for 1 month in 22 people with subacute and 19 
chronic stroke whilst participants in Smith et al.’s (2009) study received 9 minutes of sensory 20 
stimulation four times a week for six weeks. [15, 18, 44] Whilst all reported some improvements in 21 
upper limb function, none used similar outcome measures either to each other or to the current 22 
study, making direct conclusions about the effects of dose impossible. This indicates that future 23 
studies should consider the effect of dose on response to inform the clinical use of RSS.  24 
 25 
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Limitations 1 
A key limitation of this study was that the RSS and UC groups were not matched for time and 2 
attention and so the differences between groups may be simply attributable to a greater dose of 3 
therapy or the effect of more time spent with a health professional in the RSS group, and unrelated 4 
to the intervention content.  The RSS group received over 165 minutes more treatment (RSS and 5 
usual care) than the UC group during the intervention period and the treatment received after the 6 
intervention had finished was not standardised nor monitored in either group. Others have shown 7 
that more intensive treatments can elicit greater improvements in upper limb function[44] and it has 8 
been suggested that this may be independent of the content of the intervention to some 9 
degree.[42] In their randomised controlled trial of RSS in the acute/sub-acute period after stroke, 10 
Kattenstroth et al. (2018) included a time-matched control intervention (sham) and found that there 11 
were very few significant differences between groups on individual outcome measures, including the 12 
NHPT used in the current study.[21] This highlights inclusion of an appropriate sham treatment is 13 
vital in a future trial of RSS to ensure treatment times and expectations of benefit are as closely 14 
matched as possible so that the presence and magnitude of any effect of RSS can be clearly 15 
identified. 16 
Another limitation of the current study was that the groups were not fully equivalent at baseline. 17 
The RSS group was randomised to start their treatment two days earlier than the UC group, and the 18 
RSS group had slightly better function prior to their stroke (median pre-stroke mRS scores, IQR: RSS= 19 
1, 2; UC=2, 2) and marginally better stroke status (median NIHSS scores, IQR: RSS:6, 5; UC:7, 7). 20 
However, despite stratification on NIHSS arm scores the RSS group demonstrated poorer arm 21 
function at baseline (ARAT FMA-UE), suggesting that the NIHSS arm score may not be sensitive or 22 
suitable to stratify groups in a definitive trial. Other tools which could be used to stratify groups to 23 
ensure equality in a future trial include the SAFE score and/or PREP2 algorithm.[46,47] These tools 24 
have shown an ability to predict the recovery of arm function in 75% of people after stroke but are 25 
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complicated by their need to use transcranial magnetic stimulation, which may not be available in 1 
some clinical settings.[48]  2 
Despite potential practical limitations, exploration of sensorimotor cortical function does have an 3 
important role in providing an understanding of the mechanisms by which RSS may elicit changes in 4 
upper limb function after stroke. Some have reported specific reductions in GABA-ergically mediated 5 
intra-cortical inhibition in the motor cortex which can be present even after a single 2 hour RSS 6 
session in people with chronic stroke (n=9) [48] whilst others have found that a longer 4 week 7 
duration of thrice weekly RSS in people with chronic stroke did not significantly alter corticomotor 8 
excitability from baseline.[18] These findings are supported by others [19] and indicate that  the 9 
primary mechanism of RSS is likely to be potentiation via glutamatergic connections between the 10 
primary sensory and motor cortices, rather than alterations in intra-cortical excitability.[14] 11 
However, further research is needed to inform an ‘optimum’ dose of RSS to benefit motor function 12 
after stroke as inconsistencies in the data mean that there is little evidence on which to base current 13 
treatment parameters.  14 
Conclusions 15 
The results from this single blinded randomised controlled feasibility study show that RSS is 16 
acceptable to use in the early acute period after stroke and that recruitment to a trial to determine 17 
its effectiveness is feasible but is likely to require a multi-centre design. This is the first study of RSS 18 
in the acute period after stroke and showed that an RSS intervention was well-tolerated and that 19 
participants were largely adherent to the daily RSS programme over two weeks. The differences 20 
between groups at baseline suggest that a definitive trial of the effectiveness of RSS for people in the 21 
early period after stroke should consider using a more sensitive measure of arm function and/or a 22 
prognostic indicator to stratify groups to ensure equality. The RSS intervention appeared to elicit a 23 
tendency towards larger improvements during the intervention period than usual care alone, but 24 
groups were not matched for time and attention and the trial was too small to identify any 25 
21 
 
significant statistical difference. Therefore, a future trial should include a credible control 1 
intervention, such as a sham glove. The differences between the measures of upper limb function 2 
between the UC and RSS groups were most marked during the intervention and were attenuated at 3 
3 months. Whilst many studies have used a shorter intervention period than the current work, these 4 
findings suggest that further research is necessary to determine if a longer or more intensive 5 
programme of RSS could elicit larger changes in upper limb function than those seen here and to 6 
elucidate the mechanism by which RSS may improve sensorimotor function.   7 
 8 
  9 
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Table 1 Baseline characteristics of participants in the RSS and UC groups  1 
 RSS + Usual Care 
(n=23) 
Usual Care (n=17) 
Time from Stroke to Randomisation  (days)   median (IQR) 
                                                             Range 
4 (3) 
2-11 
6 (8) 
2-14 
NIHSS Arm score                                median (IQR) 
                                                             Range 
1 (3) 
1-4 
2 (3) 
1-4 
Dominant hand                                 Left 
                                                             Right 
1 (4.3%) 
22 (95.7%) 
3 (17.6%) 
14 (62.4%) 
NHSS Arm group                               1-2 
                                                             3-4 
16 (70%) 
7 (30%) 
11 (65%) 
6 (35%) 
Age                                                      Median (IQR) 
                                                             Range 
72.09 (15) 
37-90 
77.15 (21) 
53-92 
Gender                                                Female 
                                                             Male 
12 (52%) 
11 (48%) 
11 (65%) 
6 (35%) 
Pre stroke Rankin score                   Median (IQR) 
                                                              Range 
1 (2) 
0-3 
2 (2) 
0-3 
Total NIHSS Score                            Median (IQR) 
                                                              Range 
6 (5) 
2-17 
7 (7) 
2-27 
Amount of Physiotherapy             Median (IQR) 
received (in minutes)                         
                                                             Range 
580 (1180) 
 
0-3625 
520 ((838) 
 
0-1240 
Amount of Occupational               Median (IQR) 
Therapy  received (in minutes)        
                                                            Range 
520 (1210) 
 
70 -3470 
560 (1260) 
 
0-1850 
FMA-UE                                             Median (IQR) 95 (46) 104 (34) 
23 
 
                                                             Range 43-118 36-117 
FMA-UE (Section H: Sensation)     Median (IQR) 
(Maximum score:12)                       Range 
10 (4) 
0-12 
11 (5.5) 
0-12 
ARAT                                                   Median (IQR) 
                                                             Range 
26 (47) 
0-57 
39 (54) 
0-57 
NHPT Time (s)                                   Median (IQR) 
                                                             Range 
300 (151) 
29-300 
300 (259) 
27-300 
NIHSS – National Institute of Health Stroke Scale, FMA-UE- Fugl Meyer Assessment Upper Extremity, 1 
ARAT – Action Research Arm Test, NHPT – Nine Hole Peg Test, if participants could not undertake 2 
the test, they were scored as taking 300 seconds (maximum time allocated before terminating the 3 
test).  4 
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